Amedisys (AMED) Tops Q3 EPS by 2c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Amedisys (AMED) PT Raised to $64 at Jefferies
November 8, 2017 8:35 AM ESTJefferies raised its price target on Amedisys (NASDAQ: AMED) to $64.00 (from $60.00) while maintaining a Buy rating following Q3.
Analyst Brian Tanquilut said the 5% SS increase in Medicare episodes highlights early traction the company is seeing with its revamped sales force and growth initiatives.
... More